> ## Content Index
> Fetch the complete content index at: https://redfiled.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# PDS Biotechnology Terminates Phase 3 Trial of PDS0101 in HPV16+ Head and Neck Cancer
- URL: https://redfiled.com/pds-biotechnology-terminates-phase-3-trial-of-pds0101-in-hpv16-head-and-neck-cancer/
- Published: 2026-09-02T16:09:33.000Z
- Updated: 2026-09-04T15:35:13.000Z
- Description: PDS Biotechnology has terminated its Phase 3 study of PDS0101 plus pembrolizumab, citing financial constraints rather than safety concerns.
- Author: REDFILED Newsdesk
- Tags: Clinical

The registry entry for NCT06790966 now lists the Phase 3 trial status as TERMINATED, with a last update on 2 September 2026.

The study evaluated PDS0101 combined with pembrolizumab in HPV16-positive recurrent or metastatic head and neck squamous cell carcinoma.

Sponsor PDS Biotechnology states the discontinuation is based solely on financial constraints.

According to the sponsor, the decision is not related to participant safety, to PDS0101 itself, or to trial conduct.

Listed indications included unresectable head and neck squamous cell carcinoma and HPV-positive oropharyngeal squamous cell carcinoma.

This is a factual summary of a public filing or press release, not investment advice. Verify all figures against the source before acting on them.